Angelo Luca, Fausto Feu, Juan Carlos García‐Pagán, Wladimiro Jiménez, Vicente Arroyo, Jaime Bosch, Juan Rodés – 1 July 1994 – Total paracentesis is widely used in the treatment of patients with cirrhosis and tense ascites. However, very little information is available regarding its consequences on splanchnic circulation, and its effects on portocollateral blood flow have not been investigated.

Maureen M. Jonas – 1 July 1994

Fricker, Valerie Dubost, Dietmar Schwab, Christian Bruns, Christoph Thiele – 1 July 1994 – Hepatic transport of the synthetic somatostatin analog octreotide—SMS 201–995, ‐Throl—and its novel derivative N‐α‐(α‐D‐glucosyl(1–4)‐1‐deoxy‐D‐fructosyl)‐octreotide—SDZ CO‐611, N‐α‐(α‐D‐glucosyl(1–4)‐1‐deoxy‐D‐fructosyl)‐‐Throl—was studied. In rats SMS 201–995 showed a plasma elimination half‐life of 1.2 ± 0.2 hr; that of SDZ CO‐611 was 1.9 ± 0.3 hours.

Oliver Selberg, Eva Radoch, Gerhard Franz Walter, Manfred James Müller – 1 July 1994 – We investigated stable cirrhotic patients for muscle glycogen content. Muscle biopsy samples were taken of 14 patients after overnight fasting. Electron microscopy showed normal intracellular distribution of glycogen (n=8). Muscle glycogen concentration was 16.5 ± 7.1 gm/kg wet muscle weight (normal range, 10 to 20 gm/kg).

Christoph E. Broelsch, Martin Burdelski, Xavier Rogiers, Matthias Gundlach, Wolfram T. Knoefel, Thomas Langwieler, Lutz Fischer, Astrid Latta, Horst Hellwege, Franz‐Joseph Schulte, Wolff Schmiegel, Martina Sterneck, Heiner Greten, Thomas Kuechler, Gerrit Krupski, Cornelius Loeliger, Peter Kuehnl, Werner Pothmann, Jochen Schulte Am Esch – 1 July 1994 – Since living related liver transplantation was first performed in 1989, more than 150 cases have been performed worldwide, mostly in the United States and Japan.

David H. Van Thiel, Harlan I. Wright, Stefano Fagiuoli – 1 July 1994 – Because of its importance as an indication for liver transplantation, the epidemiology of chronic hepatitis B disease is presented. Current knowledge relative to the pathobiological mechanisms of hepatitis B virus—related liver disease are presented, followed by a discussion of the treatment modalities currently available for use in hepatitis B virus—related liver disease.

1 July 1994

Arieh Bomzon, Wladimiro Jiménez – 1 July 1994

Edward Gane, Bernard Portmann, Romil Saxena, Philip Wong, John Ramage, Roger Williams – 1 July 1994 – Nodular regenerative hyperplasia has not previously been reported in patients who have undergone orthotopic liver transplantation. In this report we describe the clinical, biochemical and histologic findings in nine liver transplant recipients in whom nodular regenerative hyperplasia developed between 6 and 144 mo (median, 64 mo) after transplantation.

Jean‐Bernard Otte, Jean De Ville De Goyet, Raymond Reding, Victoria Hausleithner, Etienne Sokal, Christophe Chardot, Benoit Debande – 1 July 1994 – Biliary atresia is the most frequent cause of chronic cholestasis in infants. When left untreated, this condition leads to death from liver insufficiency within the first 2 yr of life. The modern therapeutic approach consists of a sequential strategy with Kasai portoenterostomy as a first step and, in case of failure, liver transplantation. After portoenterostomy, no more than 20% to 30% of patients will live jaundice‐free into adulthood.